Methylprednisolone NDC 50090-3094

NDC codes

FDA NDC Directory

Product NDC (as listed)50090-3094Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50090-3094Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50090-3094-0	50090309400	21 TABLET in 1 BLISTER PACK (50090-3094-0)Marketed from Jul 18, 2017

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Methylprednisolone
Generic name (nonproprietary): methylprednisolone
Active ingredients: Methylprednisolone — 4 mg/1
Dosage form: Tablet
Route: Oral
Labeler: A-S Medication Solutions
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 040189
Marketing start: Oct 31, 1997
Listing expires: Dec 31, 2026
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 50090-3094_3d2362f8-b64d-417d-9dab-66d7de2c1b0aSPL ID 3d2362f8-b64d-417d-9dab-66d7de2c1b0aSPL set ID eb479561-142d-410c-84b2-988375c6a96eRxCUI 259966, 762675UNII X4W7ZR7023
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450090309400 followed by a unit qualifier and the quantity

Package 50090-3094-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 2, 2024.

Indications (excerpt from the label)

INDICATIONS AND USAGE Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require l…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 040189

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 040189
Product	Strength	Form · route	Labeler	Product NDC
Methylprednisolone	Methylprednisolone 4 mg/1	TabletOral	Proficient Rx LP	63187-160
Methylprednisolone	Methylprednisolone 4 mg/1	TabletOral	Advanced Rx Pharmacy of Tennessee, LLC	80425-0230
Methylprednisolone	Methylprednisolone 4 mg/1	TabletOral	Asclemed USA, Inc.	76420-041